262 related articles for article (PubMed ID: 30502780)
1. Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Hill-McManus D; Marshall S; Soto E; Lane S; Hughes D
Value Health; 2018 Dec; 21(12):1373-1381. PubMed ID: 30502780
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Presa M; Pérez-Ruiz F; Oyagüez I
Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore.
Pruis SL; Jeon YK; Pearce F; Thong BY; Aziz MIA
J Med Econ; 2020 Aug; 23(8):838-847. PubMed ID: 32301360
[No Abstract] [Full Text] [Related]
5. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
Klein RW; Kabadi S; Cinfio FN; Bly CA; Taylor DC; Szymanski KA
J Comp Eff Res; 2018 Aug; 7(8):807-816. PubMed ID: 29792516
[No Abstract] [Full Text] [Related]
6. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
[TBL] [Abstract][Full Text] [Related]
7. Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Hill-McManus D; Soto E; Marshall S; Lane S; Hughes D
Br J Clin Pharmacol; 2018 Jan; 84(1):142-152. PubMed ID: 28888218
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of allopurinol and febuxostat for the management of gout.
Jutkowitz E; Choi HK; Pizzi LT; Kuntz KM
Ann Intern Med; 2014 Nov; 161(9):617-26. PubMed ID: 25364883
[TBL] [Abstract][Full Text] [Related]
9. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
10. Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.
Hill-McManus D; Marshall S; Soto E; Hughes DA
Clin Pharmacol Ther; 2019 Sep; 106(3):652-660. PubMed ID: 30993686
[TBL] [Abstract][Full Text] [Related]
11. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
[TBL] [Abstract][Full Text] [Related]
14. Interventions for tophi in gout.
Sriranganathan MK; Vinik O; Pardo Pardo J; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD010069. PubMed ID: 34379791
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
Perez-Ruiz F; Díaz-Torné C; Carcedo D
J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
[TBL] [Abstract][Full Text] [Related]
16. Lesinurad: A Review in Hyperuricaemia of Gout.
Deeks ED
Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of febuxostat in chronic gout.
Beard SM; von Scheele BG; Nuki G; Pearson IV
Eur J Health Econ; 2014 Jun; 15(5):453-63. PubMed ID: 23719971
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
[TBL] [Abstract][Full Text] [Related]
20. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
